Philip Astley-Sparke is Executive Chairman and co-founder of Replimune (NASDAQ; REPL), a FCP seeded company, developing next generation oncolytic vaccines. All board and management affiliations mentioned below are current or past Forbion portfolio companies.
Previously he was the President and CEO of BioVex Inc, which developed the first oncolytic vaccine to be approved in the West following the approval of Imlygic (TVEC) by the FDA in 2015. Philip relocated the Company from the UK to the US in 2005 before the company was acquired by Amgen for up to $1bn in 2011. Subsequent to BioVex/Amgen, Philip was President at uniQure (NASDAQ; QURE) where he established their US infrastructure including at the time the world’s largest gene therapy manufacturing facility and served as the Company’s Chairman between 2016-2021.
Philip currently serves as Chairman of of Synox Limited and a board member of Engene Inc. Philip also served as the Chairman of Oxyrane from 2011 to 2020 and served on the board of Forbion acquisition Corp.
Philip received a BSc in Cellular and Molecular Pathology from Bristol University UK. He is based in Boston, MA.
True innovation is driven by a small minority who are able to create precedent rather than follow it.